{"analyses":[{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.34","estimateComment":"Reference level = Chemoradiation","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4075","paramType":"Hazard Ratio (HR)","paramValue":"1.29","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"26.6","value":"17.2"},{"groupId":"OG001","lowerLimit":"12.4","upperLimit":"30.2","value":"20.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"Distant metastasis (DM) is defined as the appearance of ≥ 1 new lesions at any site (including pleural or pericardial effusion) outside of the following: the planned treatment volume, the same lobe(s) of the lung as the primary tumor, or regional lymph nodes. Time to DM is defined as time from randomization to the date of first DM, death without DM (competing risk), or last known follow-up (censored). DM rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. One-year rates are provided. Analysis occurred after 102 progression-free survival events were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin","id":"OG000","title":"Chemoradiation"},{"description":"Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin","id":"OG001","title":"Metformin + Chemoradiation"}],"paramType":"NUMBER","populationDescription":"Eligible participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 47.2 months.","title":"Percentage of Participants With Distant Metastases","type":"SECONDARY","unitOfMeasure":"percentage of participants"}